More about GlaxoSmithKline Pharmaceuticals Limited
Fundamentals for GlaxoSmithKline Pharmaceuticals Limited
Regulatory Filings for GlaxoSmithKline Pharmaceuticals Limited
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
Technicals for GlaxoSmithKline Pharmaceuticals Limited
Price Summary
On 2026-04-30, GlaxoSmithKline Pharmaceuticals Limited's stock started at 2367.2, soared to 2370.8, dropped to 2319.4, and finished the day -1.3% down at 2336.4, with a trading volume of 113678 shares.Over the course of 52 weeks, the stock peaked at 3466.2 and hit a low of 2259.5.
The future price of GLAXO is anticipated to range from 2410.0 to 3500.0, with an expected mean price of 2992.0, according to the recommendations of 4 analysts.
Technicals
Support and Resistance: The current price is 2336.4, with support at 2278.5 and resistance at 2384.2. This range suggests that the price might move between these levels, with 2278.5 offering support and 2384.2 capping further gains for GlaxoSmithKline Pharmaceuticals Limited.Aroon: AROON is currently indicating a strong bearish trend, with Aroon Down moving higher and the Aroon Oscillator remaining low. This combination suggests that the downward price trend is likely to persist. The continued low level of the Aroon Oscillator points to ongoing bearish momentum.
Bol. Bands: The BOLL BANDS is in a neutral stance, with no clear direction indicated for the market. This lack of clarity suggests that the market may be in a state of equilibrium for GLAXO, with no strong trend emerging.
Parabolic SAR: The PSAR for GLAXO continues to signal a bearish stance, reinforcing a resistance level that could restrict upward movement. This resistance suggests that the market may remain under bearish pressure, with limited potential for breaking higher.
Stochastic: The Stochastic K-line has dropped beneath the D-line and is below 20, indicating a mildly bearish outlook. This suggests that the market might experience some downward movement, though the bearish sentiment is mild. Investors should keep an eye on this trend for further confirmation.
Tripple Moving Agerage: The Tripple MOVING AVG is showing a neutral stance, not indicating a clear upward or downward trend for GlaxoSmithKline Pharmaceuticals Limited. This suggests a period of market balance, where neither side is showing dominance.
To derive valuable insights from a company's technical performance, it is essential to first understand its fundamentals. This includes its financial health, business model, and market share. Equally important is the industry context, such as competition, consumer demand, and market trends. By examining these aspects together, investors can gain a more comprehensive view of how the company's stock behaves and whether it's aligned with its underlying value.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy
The Hidden Engine of Global Growth: Why India Is Becoming Impossible to Overlook